Mental decline in the elderly: pharmacotherapy (ergot alkaloids versus papaverine).
This is the first double-blind study in outpatients to evaluate the effectiveness of dihydrogenated ergot alkaloids (DEA) (Hydergine) versus papaverine in the treatment of selected symptoms associated with mental aging. In addition, this is the first study comparing these two pharmacologic agents in relatively young geriatric patients, with a mean age in the mid-sixties. After twelve weeks of treatment, ratings of overall clinical condition and global change showed that the 26 patients given DEA improved more than twice as much as the 27 patients given papaverine. Of the 14 individual symptoms rated, 13 improved significantly more in the DEA group than in the papaverine group. These symptoms included confusion, dizziness, unsociability, depressive mood, and mental alertness. Other data confirmed the generally superior results with DEA. In view of its demonstrated beneficial clinical actions and of its notable scarcity of contraindications or side effects, DEA appears to represent a significant pharmacologic contribution to the care of elderly persons showing selected symptoms of mental and functional decline.
D000368:Aged; D000375:Aging / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003221:Confusion / Q000188:drug therapy / Q000209:etiology; D003704:Dementia / Q000150:complications / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy / Q000209:etiology; D004088:Dihydroergotoxine / Q000494:pharmacology / Q000627:therapeutic use; D004877:Ergoloid Mesylates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos; D012920:Social Behavior Disorders / Q000188:drug therapy / Q000209:etiology; D013997:Time Factors; D014717:Vertigo / Q000188:drug therapy / Q000209:etiology
D010919:Placebos; D004088:Dihydroergotoxine; D004877:Ergoloid Mesylates; D010208:Papaverine